A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy DOI Open Access

Iuliana Mihaela Buzatu,

Ligia Gabriela Tătăranu, Carmen Duță

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2192 - 2192

Published: Feb. 28, 2025

Neovascularization is an important process in brain tumor development, invasion and metastasis. Several research studies have indicated that the VEGF signaling target has potential for reducing angiogenesis tumors. However, targeting not met expected efficacy, despite initial enthusiasm. This partly because tumors cleverly use alternative growth factor pathways, other than signaling, to restore angiogenesis. Multi-target inhibitors been developed inhibit several receptor kinases play a role development of By simultaneously affecting various kinases, these treatments can potentially obstruct angiogenic pathways are involved cancer advancement, often offering more holistic strategy focusing on just one kinase. Since 2009, FDA approved number multi-kinase receptors (e.g., VEGFR, PDGFR, FGFR, RET, c-KIT, MET, AXL others) treatment malignant diseases, including cancer. Here, we present some recent results from literature regarding preclinical clinical effects

Language: Английский

A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy DOI Open Access

Iuliana Mihaela Buzatu,

Ligia Gabriela Tătăranu, Carmen Duță

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2192 - 2192

Published: Feb. 28, 2025

Neovascularization is an important process in brain tumor development, invasion and metastasis. Several research studies have indicated that the VEGF signaling target has potential for reducing angiogenesis tumors. However, targeting not met expected efficacy, despite initial enthusiasm. This partly because tumors cleverly use alternative growth factor pathways, other than signaling, to restore angiogenesis. Multi-target inhibitors been developed inhibit several receptor kinases play a role development of By simultaneously affecting various kinases, these treatments can potentially obstruct angiogenic pathways are involved cancer advancement, often offering more holistic strategy focusing on just one kinase. Since 2009, FDA approved number multi-kinase receptors (e.g., VEGFR, PDGFR, FGFR, RET, c-KIT, MET, AXL others) treatment malignant diseases, including cancer. Here, we present some recent results from literature regarding preclinical clinical effects

Language: Английский

Citations

0